Clinical Trials

Inclusion Criteria

1. Patients must be English language proficient
2. Patients must be > 18 years old.
3. Must be able to provide informed consent
4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2.
5. NAC cohort- Newly Diagnosed stage III or IV invasive serous ovarian cancer, grades 2, 3 or poorly differentiated. 
6. PD Cohort- Patients with an 75% or greater probability of having advanced HGSC based on the clinical judgement of investigator after review of imaging and CA 125 values and who are schedule to undergo a PD surgery. 
   • Patients who have advanced HGSC confirmed at PD surgery and who undergo any attempt at surgical debulking will be considered eligible and enrolled in the PD cohort.
   • Patients with advanced HGSC confirmed at surgery and undergo diagnostic biopsy only without any debulking will be considered eligible and enrolled into the NAC cohort.
   •  Patients who have benign ovarian disease confirmed at surgery will be considered eligible and enrolled as benign surgical controls (n=10 total). 
7. Scheduled to receive i.v. or combined i.v./i.p. platinum and taxane combination chemotherapy with or without bevacizumab within 4 weeks of study enrollment.
8. Patients must have Abdominal-Pelvic CT or MRI scan within 28 days of study enrollment
9. Organ function must include the following pre-treatment parameters: 

1. white blood count (WBC) > 3,000/ul
2. Hb > 9 gm/dl %
3. Platelet count > 100,000/ul
4. serum creatinine < 1.5 mg/dl
5. serum albumin > 3.5 gm/dl
6. serum total bilirubin < 1.5 mg/dl
7. alanine aminotransferase (ALT)/ aspartate aminotransferase (AST)/ alkaline phosphatase < 2 x ULN.